Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube

Clinical Pharmacology in Drug Development

Volumn 3, Issue 4, 2014, Pages 321-327

  Moore, Kenneth T ^a   Krook, Mark A ^a   Vaidyanathan, Seema ^a   Sarich, Troy C ^a   Damaraju, C V ^a   Fields, Larry E ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bioavailability; Factor Xa inhibitor; Nasogastric tube; Pharmacokinetics; Rivaroxaban

Indexed keywords

POLYVINYLCHLORIDE; RIVAROXABAN; SILICONE; WATER; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADSORPTION; ADULT; APPLE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLEEDING; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRUSHED TABLET SUSPENSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG STABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NASOGASTRIC TUBE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POWDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; DIGESTIVE TRACT INTUBATION; DRUG FORMULATION; DRUG MONITORING; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; DRUG MONITORING; DRUG STABILITY; FACTOR XA INHIBITORS; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RIVAROXABAN; TABLETS; YOUNG ADULT;

EID: 84903767802     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.123     Document Type: Article

References (19)

1. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012; 26(1):27-32.
2. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939- an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005; 3(3):514-521.
3. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011; 10(1):61-75.
4. Cabral KP, Ansell J. Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. Nat Rev Cardiol. 2012; 9(7):385-391.
5. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78(4):412-421.
6. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61(12):873-880.
7. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006; 46(5):549-558.
8. Sarich TC, Peters G, Berkowitz SD, et al. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci. 2013; 1291(1):42-55.
9. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013; 51(7):549-561.
10. Carnaby-Mann G, Crary M. Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg. 2005; 131(11):970-975.
11. Cornish P. " Avoid the crush": hazards of medication administration in patients with dysphagia or a feeding tube. CMAJ. 2005; 172(7):871-872.
12. Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother. 1989; 33(7):1118-1120.
13. Rohde G. Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 872(1-2):43-50.
14. Gill D, Spain M, Edlund BJ. Crushing or splitting medications: unrecognized hazards. J Gerontol Nurs. 2012; 38(1):8-12.
15. Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008; 65(24):2347-2357.
16. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost. 2007; 97(6):931-937.
17. Davies NM, Takemoto JK, Brocks DR, Yáñez JA. Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet. 2010; 49(6):351-377.
18. Marathe PH, Sandefer EP, Kollia GE, et al. In vivo evaluation of absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy. J Pharmacokinet Biopharm. 1998; 26(1):1-20.
19. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol. 2003; 43(3):211-227.